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Abstract
Background
Bacterial vaginosis (BV) is associated with an elevated vaginal pH and the presence of
abnormal offensive discharge. It is common, often recurrent, and the most effective treat-
ment regimen is unknown. ‘Metronidazole Versus lactic acId for Treating bacterial vAgino-
sis’ (VITA) is a UK-based randomised controlled trial assessing clinical and cost-
effectiveness of topical lactic acid gel compared to oral metronidazole antibiotic for treating
second and subsequent BV episodes. Few BV trials report on women’s preferences for
treatment in the context of their own experiences.
Method
This qualitative study investigated the acceptability and tolerability of the two treatments.
During the trial, semi-structured telephone interviews were undertaken between January—
May 2018. A total of 33 women diagnosed with BV were consecutively sampled then inter-
viewed from six sites across England. Thematic analysis was guided by the acceptability of
health interventions framework. Potential causes of BV and its impact on women’s lives
were explored in addition to women’s treatment preference and perceived treatment
effectiveness.
Results
Although women felt antibiotics treat BV effectively, and were associated with longer time
periods between episodes, they generally preferred using the lactic acid gel because of
ease of use, once daily application and less side-effects. Women would recommend the lac-
tic acid gel to others for mild cases of BV but to take antibiotics when more severe. The risk
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of antibiotic drug resistance was a common concern. Self-help medicating or self-decision
to not treat was also evident due to prior experience of poor outcomes from treatment. Trig-
gers of BV were attributed to personal hygiene habits–soaps used to wash the vagina and
sexual practices such as unprotected sex.
Conclusion
Acceptability and preference for topical lactic acid gel or oral metronidazole tablets in the
treatment of recurrent BV was affected by personal choice relating to affective attitude, bur-
den, ethicality, intervention coherence, opportunity costs, and self-efficacy. These differed
depending on ease of use, tolerability and past experiences, but not necessarily based on
perceived drug effectiveness. Knowledge of a patient preference for topical lactic acid gel
therapy despite lower perceived effectiveness may be useful for clinicians when making
treatment decisions.
Introduction
Bacterial vaginosis (BV) occurs in the lower genital tract and is often persistent with a high
prevalence, varying from 20–50% amongst women of reproductive age. It has been described
as ‘a common condition of unknown aetiology’ [1], and as ‘a microbiological and immunolog-
ical enigma’ [2]. BV’s microbial imbalance [3] is characterised by homogenous discharge, vagi-
nal pH greater than 4.5, positive amine test and presence of clue cells microscopically [4] but
BV can also be asymptomatic. This vaginal condition may cause gynaecological and obstetric
complications, and contributes to the pathogenesis of pelvic inflammatory disease [4]. Risk
factors include African origin, low socioeconomic status, cigarette smoking, douching, new
sexual partners and recent multiple partners [3]. The ‘polymicrobial nature of BV and its pro-
pensity for recurrence make treatment a challenge’ [5].
Treatment options are associated with a high rate of microbiological and symptomatic
recurrence [6] irrespective of treatment used. At present, oral antibiotics such as metronida-
zole or clindamycin are regarded as first-line treatment for BV [7, 8] although they may only
clear symptoms transiently. [4]. Many studies have also assessed the efficacy of lactobacilli pro-
biotics administered intravaginally but with inconsistent results [9–11]. Another treatment
option is topical lactic acid gel, available without prescription, which is promoted to restore
vaginal pH balance and natural bacteria. However this is not included in current UK guide-
lines [12] and has not been adequately evaluated [13].
Treatment acceptability
In addition to clinical efficacy, Devaux, Castela [14] suggest that factors to consider when
selecting therapy include: patient treatment preference, the effect on the quality of life and the
acceptability of treatment. Kazdin [15] defined treatment acceptability as ‘treatment that is
acceptable when it is appropriate to the problem, fair, reasonable and non-intrusive to the
patient’ but it must also include the degree to which the person thinks it may be effective [16].
Greater treatment acceptance is associated with higher adherence, better compliance and
improved persistence [17]. To this end, acceptability has become a key consideration in the
design, evaluation and implementation of healthcare interventions [18]. However, very few
studies [19] have qualitatively explored acceptability and tolerability of different BV treatment
options.
Treatment preferences for recurrent bacterial vaginosis
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Clinical trial
This paper reports on the qualitative phase of a national multi-centre trial entitled ‘Metronida-
zole Versus lactic acId for Treating bacterial vAginosis (VITA): A randomised controlled trial to
assess the clinical and cost-effectiveness of topical lactic acid gel for treating second and subse-
quent episodes of bacterial vaginosis’ [20, 21]. At the time of recruitment for interview, six of
the 22 participating NHS sites were recruiting women to the VITA study. Participant inclusion
criteria included women aged 16 years or above; with clinical diagnosis of BV based on
patient-reported symptoms of unpleasant (typically fishy) odourised discharge (with or with-
out positive microscopy from swab test according to local site practice); a history of one or
more episodes of BV within the previous two years which resolved with treatment; willing to
take their own vaginal samples; avoidance of vaginal douching during treatment; and avoid
sexual intercourse or use effective contraception for the seven-day duration (condoms were
not considered safe due to interaction with lactic acid gel). Those not eligible included women
who were pregnant; breastfeeding; trying to conceive; or on other oral or topical antibiotics or
antifungals. Risks to participating included possible side effects of drugs. Women were briefed
that if the medication they were given did not work, further drugs could be prescribed. When
seen at their local general practice (GP) surgery or genitourinary medicine (GUM) sexual and
reproductive health clinic, participants were asked to take their own genital samples of vaginal
discharge for microbiological analysis of BV. Women were randomised to oral metronidazole
antibiotic tablets at a dose of 400mg, twice daily, 12 hours apart, for seven-days (control) or
5ml of intravaginal lactic acid gel (which is colourless and viscous) administered through an
intravaginal tube and inserted into the vagina, once daily before bed, for seven-days (interven-
tion). Participants obtained their allocated study treatment from any dispensing pharmacy as
any licensed brand of metronidazole or lactic acid gel could be used. Following the initial visit,
women were followed-up for resolution of their symptoms at two-weeks, three-months and
six-months. Online questionnaires, optional diaries as aide-memoire and self-sampling kits
were completed at home.
The aim of this predefined sub-study, as outlined in the trial protocol [21], was to use quali-
tative research methods to explore a diverse group of women’s experiences of the acceptability
of treatments and preferences for treatment, what factors they perceived to contribute to the
development and recurrence of BV, and how BV made them feel physically and emotionally.
Methods
Ethics statement
Ethical approval for this trial (ISRCTN14161293) was obtained from the NHS Health Research
Authority, London Harrow Research Ethics Committee: 17/LO/1245 on 09/09/2017.
This study has been reported in accordance with the 21-item ‘Standards for Reporting
Qualitative Research’ recommendations by O’Brien, Harris [22]. The lead author, JAW, an
experienced qualitative researcher, was responsible for interview recruitment, data collection
and analysis. She worked independently of the trial team and was blinded to the post-treat-
ment results.
Sub-study recruitment
Consecutive sampling of women who had completed the course of treatment and opted in to
be approached for interview were identified. It was therefore not pre-determined how many
women from each trial arm would accept an interview. Women received an email invitation
for an interview from JAW and if there was no reply, two reminder emails were sent, a week
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apart. They were also reminded that participation was voluntary and they were free to with-
draw from the interview or study at any time [21]. Interview recruitment continued until data
saturation. There were no direct benefits for taking part in the trial, except a £15 Amazon gift
voucher for completing a two-week post-intervention online questionnaire.
Data collection
Semi-structured interviews were conducted over the telephone, by JAW, between January—
May 2018 whilst the trial was still ongoing. Data was collected in English and interviews were
scheduled at least two-weeks after completing the seven-day course of treatment. We asked
women about their preferences, and the advantages and disadvantages of either treatment.
Women were encouraged to talk about their recent episode and previous episodes of BV
including symptoms, triggers and the impact of BV had on their lives to provide contextual
background (see interview guide -Appendix 1). Women were made aware of the useful nature
for us to ‘hear their voices’ in adjunct to collecting their clinical results and questionnaires at
different time points. Consent was given in writing at the trial recruitment stage and again ver-
bally at the start of each phone-call, including consent for audio-recording using an encrypted
Dictaphone. Interviews were transcribed by one of the two independent transcribers hired by
the University of Warwick.
Reflexivity
Participants were told that JAW is a health science researcher (non-clinician), experienced in
qualitative assessment, particularly in-depth interviews on sensitive topics. Throughout the
data collection process, JAW adhered to researcher self-reflexivity around personal opinions
and any experiences or preconceptions about the research. On reviewing the interviews prior
to analysis, JAW emailed participants to ask for clarifications where necessary. JAW had no
prior relationship with any of the participants.
Data analysis
Data was coded by JAW in QSR International’s NVivo version 11 using thematic analysis as
defined by Braun and Clarke [23]. Codes were based on interview questions and subsequent
emergent themes, checked by FG via inter-coded reliability for inferences and interpretation
of data. A mini-report of the first ten transcripts were analysed and shared with the wider trial
team for discussion whilst data collection continued. Word spotting of descriptive adjectives
assisted in summarising all contextual data describing BV symptoms. We present participant
quotes labelled by their age and allocated treatment group.
Theoretical framework
Comparative analysis followed, where we used data to relate findings to seven constructs in
‘The acceptability of health interventions framework’ by Sekhon, Cartwright [18] as the com-
parator. It comprises of seven multi-faceted constructs: affective attitude (how they feel about
the intervention); burden (perceived effort required); ethicality (good fit with their value sys-
tem); intervention coherence (how they understand the intervention); opportunity costs (bene-
fits, profits, values to engage); perceived effectiveness (perceived as likely to achieve its purpose)
and; self-efficacy (confidence that they can perform the behaviour required to participate). This
framework fits well with our research topic on treatment acceptability, as the constructs reflect
the extent to which people receiving a healthcare intervention, consider it to be appropriate,
based on their anticipated or experiential cognitive and emotional responses. We consider
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each construct within our data from women’s’ prospective, concurrent and retrospective per-
spectives on BV treatments.
Results
In this study, the biomedical treatment preferences of 33 women were exposed based on their
trial participation and historical medication experience. Opinions were formed based around
side-effects, perceived effectiveness, treatment outcomes, and lifestyle factors. First, we
describe demographics, response rate and adherence.
Participant demographics
We analysed interviews from the 33 women, aged 21–51 years old (average age of 32 years),
from diverse ethnic backgrounds: eleven identified as Black Caribbean, nine as White, five as
Black African, three as Mixed-race, two as Asian, one as Indian, one as Pakistani, and one as
Chinese. Our sample was representative of most ethnicities across the six sites, whereby White
and Black Caribbean, were also predominant. Our sample did not include Bangladeshi and
Black Other. They were recruited from an NHS GP surgery or GUM clinic at six study sites in
differing geographic locations in the West Midlands (19), the North (1) and the South East of
England (13). Only six sites had been recruited onto the trial at this stage. Sexual orientation
was not specifically requested, but from the interview data, we know women with both male
and female partner(s) were included. Most women had experienced on average one-three epi-
sodes of BV, but 11 women had experienced BV more than three times. In our sample, 20
women had been randomised to the trial arm (oral lactic acid gel) and 13 women to the control
arm (antibiotic tablets). Data saturation was not reached at the target sample of 20 women, so
interviewing continued to a total of 33 participants at which time saturation had been reached.
Response rate
Of the 52 women consecutively invited for an interview, a total of 33 women (who were two-
five weeks post-treatment) completed a telephone interview, lasting between 10–45 minutes.
The reasons for 19 of the women not being interviewed were: four did not answer their phones
at the agreed time (even after a second attempt the next day at the same time), 13 women
never replied to email invites, one woman decided not to take part in the interview, and
another withdrew from the study.
Adherence
Women generally adhered to and completed the treatment prescribed under the trial, although
two forgot to take their treatment on one out of the seven-day course. Two women in the inter-
vention-arm delayed starting treatment because of their menstruation bleed, and one went
ahead using the lactic acid gel regardless of her period. All women had completed treatment
before being interviewed.
The research categories are explored with related themes and described by context, treat-
ment acceptability, perceived effectiveness and preference under Sections 1–3.
Section 1: Context of bacterial vaginosis
Characteristics of the physical symptoms of bacterial vaginosis. Women described the
discharge associated with BV symptoms in terms of colour, texture, smell and physical sensa-
tions using a range of adjectives (see Box 1).
Treatment preferences for recurrent bacterial vaginosis
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How bacterial vaginosis makes women feel and the impact on their lives.
“I just don’t feel comfortable because I feel like I always smell. . . There’s nothing I can do to
mask it. Like I go through so much perfume.” (V33, aged 33: lactic acid gel)
As a result of these symptoms, women expressed how these made them feel psychologically
and physically. They described how it affected their mental wellbeing by making them feel
depressed, increasing their anxiety and self-consciousness and for one, as a ‘life sentence’. One
woman explained how she did not deal with her symptoms until breaking point.
“It got to the point where I just couldn’t get with it anymore. It was affecting me at work and
stuff, so that’s when I came in [to the GUM clinic]. So, I’ve constantly had it for a while, to be
honest.” (V11, aged 22: lactic acid gel)
BV symptoms impacted on personal relationships.
“If I have sex with him, it comes, to the extent that I feel like I need to end the relationship.”
(V45, aged 34: antibiotic tablets)
Women felt ‘embarrassed’, ‘paranoid’, ‘body conscious’ and ‘self-aware’ that their vaginal
discharge malodour was obvious to their partners, children, colleagues (especially if they
worked closely with people: nurses, teachers, support workers) and even strangers.
“I sat on the bus and I think people can smell me and I just stay away from people, you
know.” (V24, aged 37: lactic acid gel)
Episodes and recurrence of bacterial vaginosis. Several women became very emotional
when describing BV as ‘a nightmare’, and how it returns and persists, even when treated.
Some women described having BV all of the time or episodes as often as every two weeks.
“Like me now, I’ve mastered BV; I know when it’s coming.” (V45, aged 34: antibiotic tablets)
Two women said they have normalised the symptoms to the extent that they “don’t notice a
point when I don’t really have it.” (V23, aged 23: antibiotic tablets). Most women described
Box 1. Women’s descriptive adjectives of vaginal discharge texture, col-
our, smell and feel as typical symptoms of bacterial vaginosis
Colour of the discharge: dark greenish, brown, yellowy, translucent, magnolia, creamy
white, dark in colour, clear or whitish, pinky, cloudy
Texture of the discharge: solidified, crustated, mucusy, opaque, very fluid, like lotion,
watery, milky, thick
Malodour of the discharge: rancid, very smelly, sour smell, foul kind of odour, fishy,
seafood odour, potent smell, vinegary, disgusting, horrendous, stinking smell
Physical sensation associated with the discharge: itchiness, slight burning, irritation
(symptoms worsened pre- and post-menstruation)
Treatment preferences for recurrent bacterial vaginosis
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recurrent episodes as “really close to each other” (V15, aged 30: antibiotic tablets) and that it
feels inveterate.
“I’ve had it for months now. And then I get rid of it, and then it comes back again, and then I
get rid of it, and then it comes back again.” (V24, aged 37: lactic acid gel)
Women associated recurrence with poor treatment outcomes. From their perspectives, the
length of time between BV episodes was dependent on the last treatment taken:
“After taking antibiotics, came back after a few months and then a few weeks after the lactic
acid gel.” (V9, aged 37: lactic acid gel)
Due to the frequency of recurrence, many women said they did not have spare time to
repeatedly seek treatment, especially mothers.
“Sometimes I just ignore it, and with work and the baby, I don’t really get much time.” (V15
aged 30: antibiotic tablets)
There was a sense that women felt frustrated having tried every possible clinical interven-
tion available to them and felt nothing worked long-term to cure their BV.
“I was just basically at my wit’s end to try and sort this problem out. . . I feel like I’ve tried
everything.” (V18: aged 37, antibiotic tablets)
Perceived triggers of bacterial vaginosis. All of the women were confused about how
and why they get BV recurrently. Most identified noticeable contributing triggers that
impacted on recurrence. The most frequently perceived trigger that women associated with
BV were sexual practices–unprotected sexual intercourse (for example, not using condoms),
multiple sexual partners, and male semen post-ejaculation. All women attributed being sexu-
ally active to BV recurrence, if they were in or out of a relationship with a person(s) of the
same or opposite sex and practising safe or non-safe sex.
“I am practising, you know, quite unsafe [sexual] behaviour, but I’m well aware of that.”
(V41, aged 33: lactic acid gel)
Of those women who felt there was an association between their sexual behaviours and BV,
four women believed this caused a disturbance or imbalance in their vaginal pH levels due to
possible bacterial transfer.
“I seemed to notice that if I was using tampons during my periods, I would like, without a
shadow of a doubt, I knew I was going to have BV afterwards.” (V22, aged 28: antibiotic
tablets)
The use of contraceptive coils such as Intrauterine device (IUD) (copper or hormonal
implant, Mirena branded), menstrual cycle and application of tampons and not changing tam-
pons regularly or forgetting to hand wash pre-application were all viewed as contributors to
the condition. Hygiene practices that were deemed to trigger BV, such as the type of soap
product used by the sexual partner on their ‘intimate areas’; bathing in perfumed bubble bath
water; using ‘cheap’ shower gels; cleaning with an antiseptic solution such as Dettol1; or
Treatment preferences for recurrent bacterial vaginosis
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activities such as douching were described by almost all women as detrimental to the develop-
ment of BV.
“I was told not to douche or anything like that down below, as it could just disrupt the natural
bacteria inside.” (V7, aged 26: lactic acid gel)
Further factors included: other health conditions such as endometriosis or taking predniso-
lone steroid medication; type of clothing material such as non-cotton underwear; type of laun-
dry detergent such as fabric softener and wearing perfumed sanitary pads; and lifestyle
choices. For example, three women suggested that their poor diets of caffeinated energy drinks
and high-fat processed foods including crisps, chocolate, burgers, take-outs by “grabbing some-
thing from either the chip shop or McDonald’s” (V15, aged 30: antibiotic tablets) and being over-
weight were possible causes of BV; excessive cigarette smoking “eight cigarettes a day” (V18,
aged 37: antibiotic tablets); alcohol consumption particularly pinpointing the yeast in the beer
when drinking “probably eight cans and half a bottle of vodka [per day]” (V24, age 37: lactic
acid gel), were all behaviours attributed to working shifts, multiple jobs, a lack of time and
stress at work, were all mentioned.
Self-help: Changes in personal hygiene habits, self-help medication and home reme-
dies. Most women had received advice about personal hygiene to prevent BV from a health
professional in the past. Some had been recommended or prescribed dermatological soaps to
wash with, such as Cetraben1 or aqueous emollient creams. Women felt showering with a
spray, using tepid tap water and a pH balance sensitive soap were preferential to bathing in fra-
granced soap. Soap brands used were Sienna X1, Sanex Zero%1, Aveeno1, Lush1, and
Dove1. Numerous women were concerned that their body-wash products may “still feel like
it might be passing down there [vagina]” (V23, aged 23: antibiotic tablets). Almost half of the
women said they do not use soap inside of their vagina, only water. Washing habits varied
from several times per day due to religious beliefs or to remove BV discharge, or commonly
twice per day or every few days to weekly (to ‘preserve the natural body oils’). Two women did
not have access to a shower at their residence and used a bath or container to wash. Another
said she washes her hair separately to her body, so any shampoo chemicals do not contaminate
her bath water.
As a result of poor treatment effects from pharmaceutical drugs, more than half of the par-
ticipants had attempted self-help medicating before, during or after being prescribed treatment
for BV. This ranged from buying over-the-counter liquid lactic acid gels or waxy bullet-like
pessaries either from a pharmacy or online (two brands mentioned were Canesbalance1 or
Balance Activ). The cost of these lactic acid gel treatments varied from £8–20 which was
deemed unaffordable. The advice sought from online forums “of women miserable because BV
has ruined their life” (V8, aged 25: antibiotic tablets) included their suggested home remedies
such as steaming, washing with apple cider vinegar or inserting bio-live active natural yoghurt
cultures (organisms) into the vagina.
Section 2: Experiences and perspectives around acceptability and use of
treatment for bacterial vaginosis
Prior experience of treatment for bacterial vaginosis. Only one woman had never expe-
rienced using the lactic acid gel before and she was randomised to the metronidazole antibiotic
tablets. She was not aware that this was a treatment option. On the contrary and unusually,
one woman had only ever taken the lactic acid gel to treat BV before (never before prescribed
antibiotics). Another woman simultaneously sought treatment at two healthcare facilities,
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taking both the lactic acid gel and antibiotics at the same time. No women described previously
taking alternative BV treatment types such as topical metronidazole gel or clindamycin cream.
In accordance with the acceptability of health interventions framework, we established that
the following constructs aligned with our findings (Table 1).
Intervention treatment: Acceptability and ease of use of the lactic acid gel. As a treat-
ment option, intravaginal lactic acid gel administered once per day, before sleeping, was over-
all very acceptable as it was described as ‘easy to administer/apply’ ‘without a problem’ and
‘easy to use’. Out of the 20 women randomised to the lactic acid gel, 17 described the tube
applicator as comfortable to use.
Table 1. Related finding to the acceptability construct from the ‘acceptability of health interventions’ framework.
Acceptability construct Related finding
Self-efficacy: the woman’s confidence that she can
perform the behaviour(s) required to participate in the
intervention
All women sampled, were by definition, willing to
participate in the trial.
(Drug) Intervention coherence: the extent to which the
participant understands the (lactic acid gel or
metronidazole antibiotic tablets) intervention and how it
works
Lactic acid gel—application once per day, at night was
described as easy to apply to the site of the condition/ had
a soothing effect to reduce itchiness/ was possibly messy/
application was restricted to night time/ administration
was lying down.
Metronidazole antibiotics—simple to take anywhere/
some side-effects of drugs/ concern of antibiotic
resistance.
Burden: the perceived amount of effort that is required
to participate in the (healthcare) intervention (pros and
cons)
Lactic acid gel requires effort: comfortably lying down;
application only just before bedtime at night/ abstaining
from sexual intercourse for the duration of treatment
(may affect intervention) (easy to buy over-the-counter in
pharmacies (even within supermarkets and online) yet
unaffordable.
Metronidazole antibiotics have probable side-effects such
as nausea (yet no one described this); antibiotic tablets
require abstaining from alcohol (may affect intervention);
obtaining prescription for antibiotic tablets requires effort
(GP appointment/ drop-in service at the GUM
clinic = wait time/ stigma once there/ cost of travel);
course of treatment is the same length of time: seven days.
Both treatments require more effort than self-medicating
with natural home remedies, because they have to be
prescribed (physically go to the appointment) or to the
pharmacy.
The burden of taking treatment lactic acid gel or
antibiotic tablets put some women off = withdraw from
either treatment or chance symptoms go away naturally.
The burden of treatment was not enough for any of the
women to drop out or discontinue the medication during
the trial (but a few forgot on one of the treatment days).
Affective attitude: how an individual feels (emotions)
about the intervention
All women were willing to give the intervention treatment
a go, still willing to take it as an alternative despite the
lactic acid gel not curing the symptoms of BV/or at least
for only a short duration of time.
All women were willing to try alternative treatments
based on the impact BV is having on their lives/
psychosocial feelings they contended with because of the
distressing symptomatology of the condition, particularly
malodour and on having to take the antibiotics regularly
within a period of time which made one woman feel
‘rubbish’.
(Continued)
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“Yeah, it was easy to use, it was fine yeah. Simple to follow instructions and everything yeah.”
(V9, aged 37: lactic acid gel)
Few problems were described in relation to lactic acid gel usage and most women had no
difficulties in using the applicator or following the instructions (to lie flat on their backs at
night). There was a general consensus that it was straightforward ‘to squeeze out’. Other rea-
sons for advocating the lactic acid gel was due to its convenience:
“Oh, I think it’s just kind of easier, it’s more convenient. I just don’t like taking pills, so I think
the lactic acid gel was a better way.” (V15, aged 30: antibiotic tablets)
However, one woman did worry whether the tube was empty as the angle needed to admin-
ister was ‘tricky’, causing her to struggle when squeezing out all remaining lactic acid gel. She
suggested that the design of the tube could be improved by making “the tube a bit longer” (V6,
aged 28: lactic acid gel) and she felt therefore more hygienic. Some women had prior experi-
ence of using shop-bought pessaries so were already familiar with vaginal application. Mostly
everyone wore panty-liners at night during the course of treatment in case of possible seepage.
“Obviously there is some sort of drippiness that happens a bit. But as it happens mostly over-
night, it hasn’t affected me during the day at all.” (V8, aged 25: lactic acid gel)
There were no side-effects associated with the lactic acid gel, except one woman said she
had increased itching which she linked to the lactic acid gel rather than a symptom of BV.
Another woman implied that because of the time of the day the lactic acid gel had to be
applied, she forgot to use it on one occasion, as she fell asleep.
“And sometimes I just don’t remember, or I’m absolutely knackered, and as soon as I’ve sat
down on the sofa, I’ve dozed off.” (V22, aged 28: antibiotic tablets)
Table 1. (Continued)
Acceptability construct Related finding
Opportunity costs: the extent to which benefits, profits
or values must be given up engaging in the intervention
For both treatments: a change in behaviour/ lifestyle is
required.
For the lactic acid gel, women may need to abstain from
sexual intercourse/ delay until the menstrual cycle bleed is
finished
For metronidazole antibiotics, women must abstain from
drinking alcohol.
For both treatments, all women adhered to treatment.
Ethicality: the extent to which the intervention has a
good fit with an individual’s value system
All women were prepared to do whatever it takes to get
on top of the BV, ‘keep it at bay’ and not succumb to the
BV and forgo value systems in pursuit of purging BV for
good.
Taking antibiotics repetitively overtime was a concern for
some women.
Taking medication treatment was not against any of the
women’s principles since their lives were being governed
by the BV.
The associated side-effects of the treatment were not
going to be very different from anything they had
experienced in the past, mostly they had all tried one or
both treatments previously.
https://doi.org/10.1371/journal.pone.0224964.t001
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She also described how she had to change her routine during the seven days of taking the
lactic acid gel:
“I mean I’ve literally got to get myself into a ritual where I’ve got to like change my bedtime
routine to remember to do it and everything.” (V22, aged 28: antibiotic tablets)
Perceived effectiveness of the lactic acid gel. The lactic acid gel was said to be fast acting,
gave instant relief and improvement was felt and seen quickly. “I noticed a very big difference, a
very big change” (48, aged 39: lactic acid gel) in the colour and texture of the discharge, “it
started to be see-through and sticky and look like snot again.” (V5, aged 38: lactic acid gel)
All of those randomised to the lactic acid gel really wanted it to work (especially those who
despised taking antibiotics) and said they would use it ‘happily’ again in the future.
“Well I felt like, oh my god, at last something’s going to work you know, within seven days I’m
going to be fine. And I can also have a drink as well.” (V24, aged 37: lactic acid gel)
Several women illuminated that their symptoms cleared up during using the lactic acid gel,
but the majority recalled the BV recurred within one to two weeks of completing treatment as
they started presenting with the same symptoms post-treatment. They concluded that the lac-
tic acid gel “didn’t really work” (V37, aged 26: lactic acid gel) and “Yeah, it hasn’t worked, it
wasn't very good at all, to be honest with you. . . it just didn’t clear it, it’s still there. . .” (V24,
aged 37: lactic acid gel)
One woman admitted being disappointed when randomised to the lactic acid gel as she had
used it twice in the past and it had failed to work.
“Whenever I had the antibiotic, I’d be okay for a couple of weeks. So, I wanted her to prescribe
me that [the tablet].” (V33, aged 38: lactic acid gel)
Negative aspects of the lactic acid gel. Gel application every night was presented as a
‘faff’. It was described as messy for women menstruating and for another woman, it felt ‘irritat-
ing’ during the night. Two women described slight discomfort, cramping and abdominal pain
soon after application. One participant advised that the act of coughing caused excessive lactic
acid gel leakage. This caused her concern about whether she had not received the full dosage.
“I think there was still some in there still doing good, but there’s some that comes out. So, I
don’t know if it will affect it or not.” (V5, aged 38: lactic acid gel)
Another woman said, she felt she could not drink water as usual before bedtime, in fear she
would need to urinate during the night (after inserting the lactic acid gel) and was, therefore,
nervous it may all come out. Two women felt the tube had too much liquid in, which caused
one of them to think:
“I felt like I’d been overloading myself with something that was foreign to my womb. Do you
know what I mean?” (V33, aged 38: lactic acid gel)
There was disagreement about whether the lactic acid gel stayed in or leaked out. Only one
woman described the lactic acid gel as ‘gushing out’ when she stood up straight after applica-
tion (not following the instructions). Women were advised to not engage in sexual intercourse
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during the lactic acid gel treatment which for some, made it a very inconvenient form of
treatment.
Control treatment: Acceptability and ease of use of the oral metronidazole antibiotic.
Overall, antibiotics were generally not acceptable to women with BV because of the frequency
they had to be prescribed. However, metronidazole was considered an effective first-line pre-
scribed treatment, particularly for ‘intense’ cases of BV. The ease of use of taking antibiotics
was on all accounts called ‘easy to do’. One woman explained she was not restricted where she
took the antibiotic tablets which were more practical for her.
“You don’t have to change routine. People can take antibiotic tablets all the time, so it’s not
something out of the normal, out of the ordinary.” (V3, aged 27: antibiotic tablets)
Confidence in the metronidazole clearing up the BV was high because it was classified as an
‘antibiotic’ drug: “Like you know it’s going to get rid of it because it’s an antibiotic.” (V22, aged
28: antibiotic tablets)
Some women did not like taking antibiotics, whereas others were indifferent about taking
them. The willingness to take antibiotic tablets was down to: “I would like rid of that BV.” (V6,
aged 28: lactic acid gel)
Perceived effectiveness of metronidazole antibiotics. Some women felt antibiotics
started to work within the first four days of treatment when signs of the condition started
fading.
“But obviously with the metronidazole, it clears up quite quickly.” (V35, aged 27: antibiotic
tablets)
However, women who described their symptoms disappearing after completing the course
said the results were short-lived before the next episode began.
“I’ve had metronidazole, it works for like two weeks and then I’ve noticed the symptoms com-
ing back again.” (V38, aged 25: lactic acid gel)
“It improved it temporarily yeah, then it came back.” (V11, aged 22: lactic acid gel)
Another woman had a similar attitude, noticing the symptoms returning albeit after a lon-
ger duration of time, sometimes up to two months, but with some of the symptoms never fully
going.
“I’m not saying it’s not working; it’s working you could say for one month, or you could say
maximum two months. Now after I took the antibiotic tablets it’s working, but still I’ve got
discharge. But smell has gone.” (V46, aged 42: antibiotic tablets)
On the contrary, for another woman, her symptoms actually worsened throughout the
seven-day treatment regimen. She felt this indicated antibiotic resistance as she had taken met-
ronidazole several times over the years. Four women had concerns about antibiotic resistance:
“I would ask for the lactic acid gel, I don’t really like taking antibiotic, because I know your body
can become like resistant to them.” (V11, aged 22: lactic acid gel)
Others explained how the process of BV recurrence had become cyclical.
“It just keeps coming back. I’ve been taking antibiotics before, and it will clear up for a little
while, and then it will come back again.” (V7, aged 26: lactic acid gel)
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This was contradicted by those women who did not like the idea of taking antibiotics but
did so nevertheless as they believed they worked.
“I’m a type of person that doesn’t really like to take antibiotics anyway. However, you know, it
was effective.” (V35, aged 27: antibiotic tablets)
However, she explained this was not always accordingly to the prescribed instructions.
“Usually I take the five antibiotic tablets in the one day, instead of having to take the two tab-
lets for seven days.” (V35, aged 27: antibiotic tablets)
The time frame between the symptoms going and coming back seemed to differ for each
person. One woman celebrated that it had been “over a week and a half now” (V40) with still
no signs of symptoms returning. For others, it went quickly but returned just as fast.
“The metronidazole, I remember when I took it; everything was cleared up and then it just
came back out of nowhere.” (V11, aged 22: lactic acid gel)
Negative aspects of the metronidazole antibiotic. Commonly reported side-effects of
metronidazole included: generally feeling ‘rubbish’, nausea, migraines and headaches, and for
one woman, a dry mouth. Many women described the taste of the antibiotic tablets as ‘nasty’
or metallic.
“Even if I halve it, I can’t swallow them, they’re quite big. Two, the taste. And then it causes
me to be ill, makes me feel nauseated more.” (V44, aged 51: antibiotic tablets)
Two women highlighted they “don’t enjoy the idea of taking antibiotics a lot” (V22, aged 28:
antibiotic tablets) referring to them as ‘synthetic’: “I prefer not to take medication if I don’t have
to.” (V17, age 27: lactic acid gel). Many women had taken antibiotics for BV numerous times
before:
“The lactic acid gel, I prefer the idea of taking it because of the fact that you’re not pumping
yourself full of antibiotics. Because I’m quite worried about the fact that I take, I need it so
often, because I think I’ve probably had it, the antibiotic treatment, probably about eight
times altogether now.” (V22, aged 28: antibiotic tablets)
At least half of the women felt regularly taking antibiotics was not good for their body.
“I hate taking antibiotics and they kind of flushed me out.” (V8, aged 25: antibiotic tablets)
There was a strong sense from the women that they did not enjoy taking antibiotics for BV,
despite feeling the metronidazole usually worked: “Don’t want to take them again.” (V18, aged
37: antibiotic tablets)
Another negative factor against taking metronidazole was not being able to consume alco-
hol for a period of time. In two instances, the participants postponed taking the treatment for a
few days as it did not fit with her social life plans.
“It’s just in the inconvenience of when I wanted to go out for a night out or have a couple of
drinks with some friends.” (V17, aged 27: lactic acid gel)
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“With the pills, I couldn’t drink alcohol, so that’s probably more than any other reason. I was
like no, on a Friday night.” (V6, aged 28: lactic acid gel)
The process of taking the antibiotics twice per day was defined as a chore: “they’re like quite
major things that impact on your life a lot, so taking antibiotic tablets can be a bit much.” (V23,
aged 23: antibiotic tablets)
This was especially true for women who did shift work, and taking antibiotic tablets was
inconvenient:
“In terms of the actual, the timing of my antibiotic tablets, because I do shift patterns, some-
times it’s literally like I’ll just remember oh, I haven’t taken it, and it’s a couple of hours late.”
(V18, aged 37: antibiotic tablets)
Also, the procedure for accessing treatment, such as antibiotics, is not immediate. Many
women described the long lag-time before getting and then starting treatment. There were two
cases described whereby the antibiotics were taken for BV caused a yeast infection (thrush).
Section 3: Treatment preference for bacterial vaginosis
In this section, we describe individual preference based on the effectiveness of treatment (what
the women think worked); and preference based on personal choice (what would they rather
take given individual lifestyle factors/beliefs). In Table 2, we summarise the differences why
one treatment was preferred to the other, according to women’s opinions depending on the
severity of symptoms, the time interval between perceived recurrences, and the advantages
and disadvantages of both drug treatments.
Tretament preference was almost exclusively based on the severity of the symptoms.
“If it’s one of them [BV episode] where, you know, it doesn’t come with much of a smell, it’s
only the discharge, then 100%, I would choose the lactic acid gel because you want it straight
into the system, and you put it straight into the vagina. Whereas if it, I found it came with a
smell, it came with a thick discharge, then definitely the tablet because within like two days of
me having the tablet, I started, the smell goes, and the thickness of the discharge will go.”
(V16, aged 30: antibiotic tablets)
Table 2. Summary of women’s treatment preference based on differences between drug treatments.
Women’s treatment
preference depending on:
Metronidazole Antibiotics Lactic Acid Gel
Severity of symptoms Severe BV Mild BV
How often drugs can be taken Short-term treatment Long-term treatment
Perceived speed of cure Quick results (all cleared up) Quick to mid-term results
Duration between perceived
recurrence
Longer durations between episodes Shorter duration between episodes
Perceived effectiveness Know antibiotic tablets work
better = strong form of treatment
Prefers using the lactic acid gel = less
intense form of treatment
Drug option First-line treatment on the first sign of
‘severe’ symptoms
First-line treatment on the first sign of
‘mild’ symptoms
Back-up drug (if lactic acid gel did not
work the first time around)
Use in addition to antibiotic/ or straight
after a course of antibiotic
Description of treatment type Last resort treatment Substitute treatment/ precaution/
preventative treatment
https://doi.org/10.1371/journal.pone.0224964.t002
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This is a common theme, that women would choose the lactic acid gel for perceived mild
recurrences, when the BV symptoms are less severe and then switch to antibiotics for more
aggressive BV. We describe why some women have a preference for treating BV with lactic
acid gel over the antibiotics and the reverse.
Treatment preference of lactic acid gel over the antibiotic tablets. Reasons given for
preference of lactic acid gel were multiple. The primary reason was availability of lactic acid gel
without requiring healthcare consultation for a prescription. The lactic acid gel was deemed as
“less kind of invasive [than an antibiotic tablet] even though you are inserting it.” (V41, aged 33:
lactic acid gel)
This was related to antibiotics being regarded as ‘strong’ antibiotic tablets.
“I don’t like taking these strong antibiotic tablets. It just. . . I don’t know I would rather insert
a lactic acid gel you know, getting medication in my system.” (V10, aged 29: antibiotic tablets)
Women seemed content with the lactic acid gel as a treatment option based on past experi-
ence with antibiotics.
“I am, I’m much happier with the lactic acid gel than I was with the pills [antibiotics].” (V6,
aged 28: lactic acid gel)
Women who were knowledgeable about the risks of antibiotic resistance preferred to
reduce their antibiotic intake, especially since they were regular users of the same line of antibi-
otic therapy.
“[Gel] is like it’s a substitute, because I know you can become resistant to antibiotics.” (V38,
aged 25: lactic acid gel)
The concern over antibiotic resistance was raised which links to why some women were
keen to try another form of treatment:
“I am quite concerned about getting resistant to using it. And obviously it’s quite a strong drug,
metronidazole, and I’d quite like to save it in case I do need it for something quite serious in the
future. So that’s my only sort of concern with taking that, you know, continuing to take it all
the time to treat a problem that seems to never go away.” (V22, aged 28: antibiotic tablets)
The lactic acid gel was easier to remember to take and applied ‘direct’ to site of the BV, mak-
ing them feel like it will treat it more quickly and target the right area.
“When you’re taking the pill, you don’t know if it’s aiming to the right place.” (V21, aged 30:
lactic acid gel)
Side effects associated with treatment were a contributing factor to their treatment choice.
“The lactic acid gel. Because I remember that the antibiotics, I felt very tired and I really strug-
gled to wake up in the morning. And yeah, I felt like a little bit less energy, you know.” (V31,
aged 33: lactic acid gel)
With minimal side effects, once per day administration and not having to abstain from
alcohol meant it was a welcome alternative to the antibiotics.
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“The lactic acid gel, because then I can drink. Not that alcohol is the be-all and end-all of
everything.” (V40, aged 41: antibiotic tablets)
The lactic acid gel was described as bringing instant relief to symptoms such as itchiness. It
was seen as a ‘temporary fix’ and was ‘better than nothing’. The lactic acid gel was often used
as the first treatment attempted clear BV. It was also regarded as a substitute drug.
“Well it’s difficult, because none of them work for me, so I don’t know.” (V10, aged 29: antibi-
otic tablets)
One woman described how she intended to use the lactic acid gel preventatively straight
after having sexual intercourse to act as a precautionary measure aiming to reduce the chances
of BV.
“Definitely straight after sex, I’m definitely going to use the lactic acid gel. I feel like the it will
stop like things in there.” (V45, aged 34: antibiotic tablets)
Another woman revealed that she had asked her the doctor to prescribe both treatments at
the same time, so she could use them back-to-back in hope that by combining the drugs, this
may cure the BV once and for all. The ability to buy the lactic acid gel without prescription was
important to them as there is a stigma attached to going to the GUM clinic for antibiotics for
BV. It also gave women the freedom to buy lactic acid gel pessaries/tubes when it suited them,
rather than taking time off work for a GP appointment or visit to the GUM clinic, possibly a
long wait time.
“I have to say it’s worth it [self-medicating and paying for treatment] because whatever price
it was, people will buy it, because you can’t live with BV.” (V38, aged 25: lactic acid gel)
Treatment preference of antibiotics over the lactic acid gel. For some, the simple act of
swallowing the antibiotic tablets was easier and more practical and convenient than the more
physical process of inserting lactic acid gel, where they had to be at home, in a comfortable
position and “able to access that area [vagina].” (V3, aged 27: antibiotic tablets)
“I mean I think obviously taking a tablet is easier because, you know, when you take the lactic
acid gel you’ve obviously got to lie down and insert it.” (V41, age 33: lactic acid gel)
Preference for the lactic acid gel was given by those who wanted to drink alcohol on week-
ends but who favoured antibiotics if they wanted to have sexual intercourse during treatment.
The majority of women who were either randomised to metronidazole under the trial or had
prior experience taking it felt “It seems to have completely cleared up” (V22, aged 28, antibiotic
tablets). It was implied that the antibiotics cure BV quicker:
“I think it kind of went from like, I think from the next day, the smell kind of went. . . Which
was really, really good.” (V15, aged 30: antibiotic tablets)
Yet, this was dependent on the severity of the BV.
“If it was like an extreme version, case of it like it was the first time I had it; I wouldn’t be
against antibiotics, because it was so. . . it was affecting everything I was doing. But if it was
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more just like a kind of gentle recurrence where I thought, oh this is starting to be a bit differ-
ent, then I would definitely choose the lactic acid gel.” (V8, aged 28: lactic acid gel)
The lactic acid gel was described as ‘doing the trick’, however the antibiotic tablets seemed
to get rid of the BV faster as they worked more quickly and was more effective with visible
signs of the symptoms of BV going:
“The lactic acid gel is still, you know, an antidote that will get rid of it. But I find the antibiotic
tablets get rid of it quicker than the lactic acid gel.” (V16, aged 30: antibiotic tablets)
The period of time between recurrence was longer when prescribed antibiotics.
“In the future, in all honesty, I think I’d just stick to what I know, and that is the antibiotics. It
does generally clear whenever I take it.” (V39, aged 27: lactic acid gel)
Some felt the lactic acid gel was as effective as the antibiotic tablets and did not have any
preference as the treatment outcomes were the same.
“I can’t recall any side-effects. It has probably a similar result as well.” (V18, aged 37: antibi-
otic tablets)
The lactic acid gel treatment was judged as being not necessarily the best form of treatment
for curing BV but did bring instant relief.
Summary of treatment preferences. Overall, there was agreement that BV symptoms
never actually go–they just “subside”, whatever treatment was taken.
“The disadvantage I would say, that it never, that my, how would I say it, my symptoms never
completely cleared.” (V38, aged 25: lactic acid gel)
What they all have in common is none of the women has much conviction in the longevity
of the biomedical treatment available on the market.
“But on both, they. . . the BV returned after a week or two, on both of them, so I think none of
them really work for me.” (V20, aged 21: lactic acid gel)
“It did yeah, for a couple of days, but then it started to come back, slightly, not as much as it
has done in the past. But still there a bit yeah.” (V9, age 37: lactic acid gel)
“It just does not work at all. . . and in the seven-day course, no change.” (V24, aged 37: lactic
acid gel)
Poor treatment outcomes force many women to self-medicate as they are ‘fed up going to
the clinic’ (V46, aged 42: antibiotic tablets) as this meant time off from work, travelling there
and paying for parking. Related to this, one woman felt there was a stigma associated with
being seen at a GUM clinic.
“It’s almost as though there’s a stigma attached to the fact that you’re going in there but obvi-
ously when it’s just one person over a counter [pharmacy], compared to explaining your symp-
toms to a GP and then getting tested.” (V40, aged 41: antibiotic tablets)
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Another treatment preference described was to do nothing and live with the symptoms
coming and going. This choice was based on poor experiences of ineffective treatments.
“I thought right, let me ride out this thing and see how it goes. And it did reduce for a while,
but then it came back just as quick I found.” (V35, aged 27: antibiotic tablets)
Others decided to delay seeking treatment once noticing the symptoms, then watching and
waiting for the BV to disappear and if not, eventually access healthcare.
“I didn’t actually go and seek any help at that point. And then I waited a few months.” (V41,
aged 33: lactic acid gel)
Recommendation of treatment for bacterial vaginosis by study particpants to other
women. Women were not completely convinced by either treatment as a long-term cure for
vaginal recurrence. They had firm reasons for why and when they would recommend either the
control or intervention treatment to someone else in their position. If it was her first episode,
many endorsed the ‘milder’ lactic acid gel as a ‘top-up’ type treatment for minor cases of BV.
“I think in my mind, it feels like a milder dose, you know, way of treating it rather than just
going straight to the antibiotics. But if they were having a recurring episode, I would suggest
the pill [antibiotic].” (V33, aged 38: lactic acid gel)
However, several women specified how their recommendation was dependent on the sever-
ity of symptoms, implying that taking antibiotics was a safer bet to clear up more moderate to
severe BV.
“I think if somebody’s genuinely got, you know, they’ve had it for a while and they’ve got a
quite a bad case of BV, I think start with the antibiotics to make sure you 110% get rid of it.”
(V22, aged 28: antibiotic tablets)
Whilst, many of the women would not immediately opt for the antibiotic tablets because of
their reservations described above, one woman felt she would rather be prescribed both the
lactic acid gel and antibiotic tablets as a full proof method to ensure ‘it doesn’t come back’.
“So, if I’m given the lactic acid gel and the antibiotics just in case it didn’t clear up, I’d be
happy to take the lactic acid gel again.” (V7, aged 26: lactic acid gel)
“You know, well to me they both work, so I would probably advise both of them.” (V41, aged
33: lactic acid gel)
Similarly, time periods between episodes were longer if antibiotics had been taken.
“Probably the antibiotics, because it seemed to get rid of it for longer.” (V9, aged 37: lactic acid gel)
There were women in the other camp that felt the lactic acid gel worked well enough and
they would be happy to be on it for longer periods of time. Some women were not able to say
which they would recommend because, for them, neither treatment had been effective:
“Well it’s difficult, because none of them work for me, so I don’t know.” (V10, aged 29: antibi-
otic tablets)
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Discussion
Women with recurrent BV found both treatment options: intravaginal lactic acid gel and oral
metronidazole acceptable but favoured antibiotics as the most effective treatment option when
the symptoms were severe, as this was perceived as having a more sustained effect. Yet in con-
trast, many women still preferred using the lactic acid gel, regarded as an easy, once per day
application with few side-effects. Although adequate for mild cases of BV, the effectiveness of
the lactic acid gel was a concern. However, the perceived rates of recurrence after using the lac-
tic acid gel and antibiotic regimens varied between individuals.
Preference for the lactic acid gel was based on pro-factors such as, application straight to
the site of the BV, offering instant soothing; concerns that frequent use of antibiotics would
lead to resistance; and the availability of the lactic acid gel without prescription, even when this
involved paying for it. The effort required to take the antibiotic tablets twice per day and alter
social behaviours, such as drinking alcohol, played a significant role in shaping acceptability
attitudes. This was often based on individual’s ideas around the practical advantages and dis-
advantages of each treatment, rather than whether it would actually work (burden). How the
BV made women feel, why they were prepared and willing to try the treatment again or for the
first time (affective attitude), and what they had to change as a result such as lifestyle practices
or behaviours (opportunity cost) had a considerable influence on their decisions. Women’s
treatment preferences did not always come down to effectiveness as these were often related to
the woman’s value system and beliefs, and the possible consequences of treatment (ethicality).
All of which can be considered by the clinician prescribing the next course of treatment at the
next episode.
Both treatments reduced discharge and the associated odour to some degree, sometimes
within a day of starting medication. Our data suggest that women were able to take the medi-
cation according to the instructions, with only some intrusion into their daily lives (self-effi-
cacy). All women held some level of understanding about how the lactic acid gel or antibiotic
tablets worked to cure the BV (coherence).
All of the women described optimism for the lactic acid gel as a future alternative or
replacement treatment for metronidazole. It was proposed that using both treatments back-to-
back may be beneficial at keeping the BV at bay or by using the lactic acid gel as a precaution-
ary preventative prophylaxis over prolonged periods, even when there was no clinical diagno-
sis of BV. The decision to not treat was also evident amongst several women who felt poor
prior treatment outcomes lessened their confidence in a cure. The hope that the condition
would just go away without treatment was popular. However, they also recognised that a point
was often reached at which the BV became unmanageable, when treatment in whatever form
was sought and led to the emotional and physical despair reported by every woman in this
sub-study. Treatment preference was therefore down to personal choice, which differed
depending on drug accessibility and current lifestyle, and was not necessarily focused on effec-
tiveness. Since the trial is still ongoing (July, 2019) the comparative effectiveness of the lactic
acid gel and metronidazole are still unknown to the research team.
The multifaceted nature of BV’s aetiology makes the management of acute and recurrent
symptoms complicated as women’s experiences in the current study attest. Our data highlight
how women with symptomatic BV have tried prescribed and self-medicated treatment options
multiple times. They oscillated between which treatments they prefer, as neither lactic acid gel
nor metronidazole antibiotic tablets were seen as having particularly sustained outcomes, with
symptoms described as never really going away.
The characteristics of BV such as offensive smell and abnormal vaginal discharge that so
impact on women’s lives are consistent with findings from other qualitative studies [1, 24]. We
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similarly found that the impact recurrent BV had on women’s lives goes beyond the bacterial
symptomatology and leads to emotional trauma. In parallel, an increase in paranoia and
reduced self-esteem affected women’s’ work and personal relationships due to the physical,
emotional and social burden of living with recurrent BV [19].
There is a complex interaction of multiple components: the vaginal microbial ecosystem
and the human host which is modulated by a woman’s behaviour and environment, which fur-
ther complicates the overall ‘BV cause equation’ [3]. A qualitative study documenting Swedish
women’s BV life experiences and management of symptoms, also found that BV influences
quality of life including reduced intimacy, changes in relationships and frustration around
recurrence [25]. Research into African American women with BV found that lifestyle behav-
iours such as douching, bathing and using vaginal cleaning agents were significantly associated
with BV due to the disruption of vaginal flora [26]. Whilst women in the current study did not
report these specifically, descriptions around hygiene practices as probable triggers were iden-
tified. In addition, the frequent use of self-help remedies to counteract BV was also identified
in our participant group. Payne, Cromer [26] reported the potential for hormonal contracep-
tives to protect against BV, yet this was at odds with several women in our study, who felt there
was in fact a correlation between BV and their copper coil in causing BV.
In a study by McGowan, Gomez [27], reasons for not accepting the lactic acid gel were
messiness and leakage. This was seldom reported in our study, as lactic acid gel was regarded
as ‘easy to use’ and non-irritating which is consistent with results from Coggins, Blanchard
[28]. In our sample, women who did not prefer the lactic acid gel primarily attributed this to
having to remember to insert it at night. Our results are congruent with Bilardi, Walker [19]
who described how women in Australia were frustrated and dissatisfied with current treatment
regimens for BV, in particular antimicrobials, leading women to take ineffective non-evi-
dence-based therapies [24].
Strengths and limitations
Our study findings extend the existing literature by hearing from an ethnically diverse group
of women about their treatment experiences and views of BV which are valuable for practice
and will help to contextualise the trial results when available. As most women had experienced
various treatments, they were able to make comparisons for themselves and these prospective,
concurrent and retrospective accounts gave richness to the narratives captured. However, this
did mean that their experiences of different treatments sometimes merged together. They
found it hard to differentiate between the most recent or previous medication (which may
have been the same or different) as they were often taken so close together.
Although we aimed to interview women within two-weeks post-treatment, some interviews
were delayed up to five-weeks (due to participant availability) therefore women’s recall may
have become less accurate. We did not have sufficient data to undertake comparisons between
demographic groups or on socioeconomic variation.
This paper has not been influenced by the quantitative results of the ongoing trial.
Future implications
At present there is inconclusive evidence about what treatment regimen is most effective for
women with recurrent BV. Our interview study would suggest, in this situation, women
should be given the choice by their clinician of which treatment they prefer and/ or works best
for them given their past personal experience. However, when the VITA trial results are avail-
able, this may change. If lactic acid gel is found to be the more effective treatment option, we
know many women would welcome this as many prefer it. If antibiotics are found to be most
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effective, in many instances, women are likely to still want to use lactic acid gel because some
women are hesitant to keep using antibiotics on a recurrent basis. To achieve better informed
and shared decision-making about treatments, health professionals need an understanding of
what women think about the use of antibiotics or topical lactic acid gel (as this may affect
adherence to treatment and BV recurrence) in weighing up the pros and cons of treatments
with women. Future qualitative studies are fundamental as there are still gaps related to BV,
lifestyle and sexual orientation.
Approaches to tackling this common and debilitating condition need to take account of the
individual’s prior experiences and retrospective acceptability by reflecting on constructs such
as self-efficacy, ethicality and intervention burden, to find the best ‘treatment fit’ for each
woman. Further research that considers acceptability and tolerability of BV drug options by
individual preference and perceived treatment effectiveness will be necessary, if lactic acid gel
is to be recommended in future treatment guidelines for clinicians to follow.
Appendix 1. VITA study interview guide
Introductions
Introduction of researcher. Reminder of study (interviewee will have received participant
information sheet and signed consent form). Ask for verbal consent again on the phone and
for them to confirm their full name and date of birth.
Confirmation that participant is happy to proceed. Explanation of what happens to the
data:
• Telephone interviews will be audio recorded. The audio recordings will be stored securely.
For analysis the recording will be transcribed and anonymised.
Reminder that the interviewee can stop the interview at any time.
Opening questions
Tell me about your experiences while taking part in the VITA study?
What do you think causes your BV, if anything?
What impact does BV have on your life?
Focusing on the treatment
Thank you. Tell me about the treatment drug you received/were randomised to for the study.
Probes used as needed:
What were your initial expectations of the treatment?
Tell me how you used it.
What was good about the treatment?
What was not so good about the treatment?
Any difficulties with using it?
Did you have to change what you do day to day when using it?
How satisfied are you with the treatment you received overall?
Focusing on the modifications to make it more acceptable
Is there anything that you would add to or change about the treatment you received?
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Is there anything else that you would like to say about the treatment?
Would you recommend treatment to other women with similar problems to your own?
Probes:
• Explore reasons for their response.
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